L-Phenylalanine, L-?-aspartyl-L-threonyl-L-leucyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-leucyl-L-?-glutamyl-L-isoleucyl-L-alanyl-L-seryl-L-cysteinyl-L-leucyl-L-?-glutamyl-L-lysyl-L-alanyl-L-leucyl-L-glutaminyl-L-valyl-
Metastatic Melanoma
IO Biotechprotein_peptidePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 73/ 100
Competitive context
86 Active assets in the Metastatic Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DACARBAZINE Shanghai Junshi Bioscience Co., Ltd. | Phase 4 | BBB |
Nivolumab Bristol-Myers Squibb | Phase 4 | BB |
TIL East Metropolitan Health Service, Australia | Phase 2 | BB |
Ipilimumab NYU Langone Health | Phase 4 | BB |
Relatlimab Bristol-Myers Squibb | Phase 4 | BB |
View all 50 →
Same molecule, other indications
L-Phenylalanine, L-?-aspartyl-L-threonyl-L-leucyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-leucyl-L-?-glutamyl-L-isoleucyl-L-alanyl-L-seryl-L-cysteinyl-L-leucyl-L-?-glutamyl-L-lysyl-L-alanyl-L-leucyl-L-glutaminyl-L-valyl- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →